Your session is about to expire
← Back to Search
Diabetes Prevention Program + Support Services for Obesity (SCULPT-Job Trial)
SCULPT-Job Trial Summary
This trial is looking at how well weight loss, weight maintenance, and cardiovascular disease work in people who are disadvantaged.
SCULPT-Job Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SCULPT-Job Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You had a heart attack, stroke or cardiac arrest within the last 2 years.You are from a disadvantaged background.You have been diagnosed by a doctor with a cognitive, developmental or psychiatric condition, or had orthopedic surgery within the past six months.
- Group 1: Diabetes Prevention Program
- Group 2: Diabetes Prevention Program + Job and Legal Services
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there current availability for participants in this trial?
"According to the clinicaltrials.gov database, this medical study is not currently recruiting patients. While it was initially posted in February 2021 and last edited on August 2022, there are presently 1709 other experiments looking for volunteers."
What are the major aims of this research endeavor?
"The primary outcome we will be gauging throughout the course of this trial, extending for 12 and 18 months respectively, is BMI Maintenance. Secondary indicators include Binge eating which will be evaluated by assessing frequency through Framingham Heart Study protocols as well as intensity with a 16-item scale (BES). We'll also assess Impulsivity via self-reported responses to the Barratt Impulsiveness Scale, in addition to Cellular Aging Biomarkers using qPCR assays on fingerprick blood samples taken at baseline and after one year; telomere length measurement has an inter-assay coefficient of variability of 3.7"
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger